These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1838936)

  • 1. A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
    Yu B; Zhou G; Wang B; Ben Y; Yan H; Shao Y; Wang B
    Chin Med Sci J; 1991 Sep; 6(3):166-8. PubMed ID: 1838936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
    Bohn M; Kraemer K
    J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
    Täuber A; Müller-Goymann CC
    Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onychomycosis and AIDS: treatment with topical ciclopirox olamine.
    Dompmartin D; Dompmartin A; Deluol AM; Coulaud JP
    Int J Dermatol; 1990 Apr; 29(3):233. PubMed ID: 2139871
    [No Abstract]   [Full Text] [Related]  

  • 6. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
    Jaiswal A; Sharma RP; Garg AP
    Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
    J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
    Jue SG; Dawson GW; Brogden RN
    Drugs; 1985 Apr; 29(4):330-41. PubMed ID: 3158508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onychomycosis due to Microsporum gypseum.
    Romano C
    Mycoses; 1998; 41(7-8):349-51. PubMed ID: 9861844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
    Schalka S; Nunes S; Gomes Neto A
    An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
    Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
    Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
    Subissi A; Monti D; Togni G; Mailland F
    Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.
    Aly R; Maibach HI; Bagatell FK; Dittmar W; Hänel H; Falanga V; Leyden JJ; Roth HL; Stoughton RB; Willis I
    Clin Ther; 1989; 11(3):290-303. PubMed ID: 2663159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
    Galitz J
    Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of the antifungal efficacy of poloxamer 407-based formulations in an infected nail plate model.
    Täuber A; Müller-Goymann CC
    Int J Pharm; 2016 May; 505(1-2):20-3. PubMed ID: 26992819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer.
    Sardana K; Garg VK; Manchanda V; Rajpal M
    Br J Dermatol; 2006 Mar; 154(3):573-5. PubMed ID: 16445808
    [No Abstract]   [Full Text] [Related]  

  • 17. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
    Brenner MA; Harkless LB; Mendicino RW; Page JC
    J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro model of infected stratum corneum for the efficacy evaluation of poloxamer 407-based formulations of ciclopirox olamine against Trichophyton rubrum as well as differential scanning calorimetry and stability studies.
    Täuber A; Müller-Goymann CC
    Int J Pharm; 2015 Oct; 494(1):304-11. PubMed ID: 26276254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.